EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The investigators aim to investigate whether incorporating on-treatment EBV DNA surveillance
for monitoring tumor responses to treatment and for guiding individuliased treatment
adaptation can improve prognosis in nasopharyngeal carcinoma patient . For patients with
detectable EBV DNA after one cycle of IC, which then drops to undetectable levels during the
following IC cycles (intermediate responders/intermediate relapse risk), the investigators
aim to investigate whether additional adjuvant metronomic capecitabine would benefit this
subgroup. For patients with detectable EBV DNA after three cycles of IC or with EBV DNA
bounce during the induction phase (insensitive to IC/high relapse risk), the investigators
aim to investigate whether concurrent administration of anti-PD-1 therapy during the
following treatment phases (including concurrent phase and adjuvant phase) can benefit this
subgroup.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
First People's Hospital of Foshan National Cancer Centre, Singapore Wuzhou Red Cross Hospital